Xalkori bags FDA green light for rare paediatric non-Hodgkin lymphoma
Therapy approved for the treatment of paediatric patients with anaplastic large cell lymphoma
Read Moreby Lucy Parsons | Jan 18, 2021 | News | 0
Therapy approved for the treatment of paediatric patients with anaplastic large cell lymphoma
Read Moreby Anna Smith | Feb 15, 2019 | News | 0
NICE has recommended use of Alunbrig for treating ALK-positive advanced non-small-cell lung cancer after Xalkori on the NHS in England and Wales.
Read Moreby Selina McKee | Sep 26, 2018 | News | 0
Takeda’s Alunbrig cut the risk of disease progression or death by more than 50% compared to Pfizer’s Xalkori in adults with ALK+ non-small cell lung cancer.
Read Moreby Selina McKee | Jul 26, 2018 | News | 0
Takeda’s Alunbrig has beaten Pfizer’s Xalkori on progression-free survival (PFS) in a Phase III trial testing its efficacy as a front-line treatment for ALK-positive lung cancer.
Read Moreby Selina McKee | Jun 12, 2018 | News | 0
The Scottish Medicines Consortium has approved NHS funding for six new therapies, offering patients new options for leukaemia, epilepsy, lung cancer, plaque psoriasis, and carcinoid syndrome-related diarrhea.
Read Moreby Selina McKee | Jan 17, 2018 | News | 0
Pfizer’s Xalkori has been turned away by the National Institute for Health and Care Excellence to treat ROS1-positive advanced non-small cell lung cancer.
Read Moreby Selina McKee | Oct 17, 2017 | News | 0
Pfizer has presented Phase II data showing that its next-generation tyrosine kinase inhibitor lorlatinib exhibited “clinically meaningful activity” against lung tumours and brain metastases.
Read Moreby Selina McKee | Apr 10, 2017 | News | 0
Roche has presented late-stage data showing that its Alecensa was superior to Pfizer’s Xalkori on progression-free survival in patients with a specific type of lung cancer.
Read Moreby Selina McKee | Nov 10, 2016 | News | 0
Cancer patients will likely get routine access to Novartis’ Afinitor and Pfizer’s Xalkori on the NHS after a positive recommendation was handed down from the National Institute for Health and Care Excellence.
Read Moreby Selina McKee | Sep 1, 2016 | News | 0
The European Commission has widened the scope of Pfizer’s Xalkori to include the treatment of adults with ROS1-positive advanced non-small-cell lung cancer.
Read Moreby Selina McKee | Jul 12, 2016 | News | 0
Scottish cost regulators have endorsed the use of five new medicines by NHS Scotland, offering patients new options for lung cancer, depression, ankylosing spondylitis and epilepsy.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
